PRESCRIRE'S RATINGS OF NEW PRODUCTS AND INDICATIONS
OVER THE PAST 10 YEARS (a)
|
|
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
 |
BRAVO |
| 0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
 |
A REAL ADVANCE
|
| 0 |
1 |
0 |
1 |
0 |
2 |
3 |
1 |
1 |
2 (b) |
 |
OFFERS AN ADVANTAGE
|
| 3 |
3 |
3 |
3 |
6 |
5 |
5 |
5 |
9 |
11 (c) |
 |
POSSIBLY HELPFUL
|
| 14 |
22 |
13 |
14 |
12 |
15 |
15 |
9 |
18 |
22 |
 |
NOTHING NEW
|
| 62 |
49 |
53 |
42 |
48 |
35 |
43 |
56 |
45 |
50 |
 |
NOT ACCEPTABLE
|
| 19 |
19 |
16 |
15 |
15 |
19 |
15 |
16 |
15 |
9 (d) |
 |
JUDGEMENT RESERVED
|
| 6 |
3 |
7 |
7 |
9 |
10 |
6 |
5 |
4 |
5 (e) |
| TOTAL |
104 |
97 |
92 |
82 |
90 |
87 |
87 |
92 |
92 |
99 |
The year
in review
|
2009
(pdf) |
2010
(pdf) |
2011
(pdf) |
2012
(pdf) |
2013
(pdf) |
2014
(pdf) |
2015
(pdf) |
2016
(pdf) |
2017
(pdf) |
2018
(pdf)
|
| |
For details on these categories, see: > Prescrire's drug ratings |
Download the complete review:
"Drugs in 2018: a brief review" Prescrire Int 2019; 28 (203): 105-107. (Pdf, free)
a- About this table
This table includes new products (except copies) and new indications, as well as our updated reviews.
The results for 1981 to 2008 are available (in French only) in Rev Prescrire n° 213 and Rev Prescrire n° 304.
b- The drugs rated "A REAL ADVANCE" in 2018 were:
- sebelipase alfa in lysosomal acid lipase deficiency (Prescrire Int n° 200)
- nasal naloxone for emergency treatment of opioid overdose (Prescrire Int n° 199).
c- The drugs rated "OFFERS AN ADVANTAGE" in 2018 were:
- arsenic trioxide in acute promyelocytic leukaemia (Prescrire Int n° 193);
- lidocaine + prilocaine in premature ejaculation (Prescrire Int n° 197);
- canakinumab in periodic fever syndromes (Prescrire Int n° 198);
- lopinavir + ritonavir oral solution for HIV-infected children from 14 days of age (Prescrire Int n° 198);
- everolimus in epilepsy associated with tuberous sclerosis complex (Prescrire Int n° 199);
- captopril oral solution (Rev Prescrire n° 418);
- etilefrine in priapism (Rev Prescrire n° 420);
- sofosbuvir alone or combined with ledipasvir for adolescents with chronic hepatitis C (Rev Prescrire n° 421);
- glecaprevir + pibrentasvir in chronic hepatitis C (Prescrire Int n° 202);
- midostaurin in certain types of acute myeloid leukaemia (Prescrire Int n° 201);
- sofosbuvir + velpatasvir + voxilaprevir in chronic hepatitis C (Prescrire Int n° 203).
d- The drugs rated "NOT ACCEPTABLE" in 2018 were:
- dabrafenib and trametinib combined for certain types of lung cancer (Prescrire Int n° 193);
- pembrolizumab in Hodgkin lymphoma with no further treatment options (Prescrire Int n° 195);
- obeticholic acid in primary biliary cholangitis (Prescrire Int n° 197);
- daclizumab in multiple sclerosis (Prescrire Int n° 195);
- bezlotoxumab for recurrence of Clostridium difficile infection (Prescrire Int n° 197);
- oral cladribine in multiple sclerosis (Prescrire Int n° 196);
- olmesartan for hypertension in children (Prescrire Int n° 199);
- penicillamine in lead poisoning (Rev Prescrire n° 418);
- ribociclib in locally advanced or metastatic breast cancer (Prescrire Int n° 202).
e- The drugs rated "JUDGEMENT RESERVED" in 2018 were:
- lenalidomide maintenance therapy in multiple myeloma (Prescrire Int n° 196);
- eltrombopag in chronic immune thrombocytopenia from 1 year of age (Rev Prescrire n° 416);
- nusinersen in spinal muscular atrophy (Prescrire Int n° 199);
- avelumab in metastatic Merkel cell carcinoma (Rev Prescrire n° 418);
- dinutuximab beta in neuroblastoma (Prescrire Int n° 201).
©Prescrire 1 April 2019
"Drugs in 2018: a brief review" Prescrire Int 2019; 28 (203): 105-107. (Pdf, free)
| Share |
 |
 |
